In this Issue:
mCRC
Bevacizumab plus capecitabine in elderly patients
RAS mutations predict negative response to anti-EGFR
No survival benefit with erlotinib maintenance therapy
Second-line bevacizumab independent of KRAS status
Promising efficacy with XELOX plus bevacizumab and imatinib
CRC
PIK3CA mutations predict survival benefit with aspirin
Intensive vs minimal monitoring for recurrence
FOBT screening persists after 30 years
Inflammatory markers predict recurrence
Incidence and mortality reduced with lower endoscopy
Please login below to download this issue (PDF)